Saeid Babaei

Dr. Babaei’s track record includes over 20 years of academic and corporate experience, during which he has led several novel and first-in-class product opportunities to either commercialization or late-stage development. He brings tremendous business foresight having closed over 15 licensing and strategic alliance transactions, as well as raising over $50 million in equity and debt financing. Dr. Babaei is currently the Chairman and CEO of Orpheus Medica, a Canadian biopharmaceutical engaged in R&D and commercialization of cannabinoid-based drugs for “Orphan Diseases”. Before Orpheus, Dr. Babaei founded AbCelex Technologies that had successfully developed a series of antibody-based products for animal health and food safety. Before AbCelex, he was the VP of business development at Aptose Biosciences, where he was responsible for product and technology in- and out-licensing, strategic planning and corporate finance. Dr. Babaei holds a PhD and an executive MBA, both from the University of Toronto. He has authored over 50 publications including research papers, conference presentations and patents. He is former Chairman of the Board of BriaCell Therapeutics and Vaxil Bio Ltd, both clinical-stage immuno-oncology companies listed on TSX-V.